Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Health Canada grants SQI license to market IgX PLEX Celiac Panel

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it has received a license from Health Canada permitting the Company to market its IgX PLEX™ Celiac Panel, a quantitative 4-plex panel, which will run on SQI's automated SQiDworks™ Diagnostics Platform.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Blood levels of inflammation-controlling protein linked to childrens' risk of developing diabetes

Decreasing blood levels of a protein that helps control inflammation may be a red flag that could help children avoid type 1 diabetes, researchers say.

28 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it and AstraZeneca filed a lawsuit against Dr. Reddy's Laboratories (Dr. Reddy's) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets.

25 Apr 2011

Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA

Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis which has been posted for the European League Against Rheumatism conference.

25 Apr 2011

New genetic discovery in Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis (PF).

21 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company's Biologics License Application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.

18 Apr 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Health Canada grants SQI license to market IgX PLEX Celiac Panel

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Blood levels of inflammation-controlling protein linked to childrens' risk of developing diabetes

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Researchers discover molecular mechanisms behind autoimmunity

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA

New genetic discovery in Pulmonary Fibrosis

Study shows neutralizing antibodies against GM-CSF can halt MS development

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Prism Pharmaceuticals to be acquired by Baxter

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in